Trial reportThe lancet. HIV2025
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study.
Trial report in The lancet. HIV, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV.Antimicrobial agents and chemotherapy · 2026Observational
- Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review.Clinical pharmacokinetics · 2026Review
- Treating HIV-associated tuberculosis in children without compromise.The lancet. HIV · 2025Article
- Establishment of antiretroviral pediatric registry: efforts toward achieving the UNAIDS 95-95-95 targets in the Free State Province, South Africa.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundData on the safety and pharmacokinetics of dolutegravir in children with HIV and tuberculosis are scarce. We aimed to determine the pharmacokinetics and safety of dolutegravir 50 mg twice daily in children receiving rifampicin, and to predict exposures for once-daily dolutegravir with rifampicin.
methodsORCHID is an open-label, sequential, prospective cohort study in children (<18 years) weighing 20-35 kg initiated on a rifampicin-based tuberculosis regimen and dolutegravir in Durban, South Africa. We collected seven plasma samples over one dosing interval from each patient while on dolutegravir 50 mg twice daily during tuberculosis treatment and while on dolutegravir 50 mg once daily after tuberculosis treatment discontinuation. Pharmacokinetic data were analysed using population modelling in NONMEM version 7.5. The final model was used to perform Monte Carlo simulations in silico of once-daily dolutegravir dosing and time below target concentration (0·064 mg/L). Participants underwent regular clinical and safety visits. HIV viral load was measured at weeks 8, 12, 24, and 48. Primary outcomes were trough concentration (C
findingsBetween Aug 19, 2021, and Aug 17, 2023, we enrolled and followed up 13 children, with a median weight of 23·8 kg (IQR 21·7-24·8) and median age 10 years (range 5·9-13·0). Seven were male, six female, and 13 Black. Typical dolutegravir clearance was 0·584 L/h (95% CI 0·492-0·724), with an increase in clearance of 99·1% (73·2-120) with rifampicin. Median C
interpretationTwice-daily dolutegravir with rifampicin in children weighing 20-35 kg achieved therapeutic concentrations and was well tolerated with high rates of viral suppression. Simulations suggest that once-daily dolutegravir during rifampicin co-administration in children weighing 20-35 kg should be investigated in clinical studies.
fundingNational Institutes of Health and South African Medical Research Council.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.